DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Walmart, Lowe's, Intuit, Kraft Heinz and more
▼ + stars: | 2024-11-19 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Walmart — The big-box retailer saw shares jump nearly 5% to hit a record after the retail giant topped fiscal third-quarter earnings and revenue expectations. The retailer also hiked its outlook again as it saw growth in e-commerce and improvements in sales outside of the grocery aisles. Lowe's — The home improvement retailer dropped more than 3% after saying it expects sales to decline in 2024 . Kraft Heinz — The packaged food company dipped about 1% after a Piper Sandler downgrade to neutral from overweight. Insmed — Shares rallied more than 8% after the drugmaker terminated a $500 million equity sales agreement with health-care investment bank Leerink Partners.

Persons: Young, Lowe's, Kraft Heinz —, Piper Sandler, Kraft Heinz, Robert F, Kennedy Jr, Trump, —, Wall, Symbotic, Donald Trump's, Jesse Pound, Yun Li, Sarah Min, Alex Harring, Sean Conlon, Pia Singh Organizations: Walmart, BDO, Ernst, Nasdaq, Leerink Partners, Viking Holdings, Revenue, Intuit, Washington Post, Donald Trump's Department, Government

☆ 2 health stocks are buys. They've been beaten up enough on Trump's RFK Jr. pick for HHS
▼ + stars: | 2024-11-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Following Monday's trade, Jim Cramer's Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. Since the election, Danaher shares have fallen from $250 each to $230 while Eli Lilly shares have dropped from $806 to $720. LLY YTD mountain Eli Lilly YTD Eli Lilly shares fell from $903 to $846 after a disappointing third-quarter report where inventory destocking of its fast-selling GLP-1 medications caused the company to miss estimates and lower full-year guidance. But the possible appointment of RFK Jr. has created a whole host of uncertainty for Eli Lilly and the drug stocks at large. If you look out to 2026, Lilly shares are trading at roughly 24 times.

Persons: Jim Cramer's, Donald Trump, Robert F, Kennedy Jr, We're, Danaher, Eli Lilly, Bioprocessing, Eli Lilly's, Lilly, Jim Cramer, Jim Organizations: DHR, Care Sector Fund, Department of Health, Human Services, RFK Jr, National Institutes of Health, HHS, CNBC Locations: Danaher

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Tesla, Meta, Snowflake, Walmart, Wells Fargo, Alphabet & more
▼ + stars: | 2024-11-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: Loop initiates NXP Semiconductor as buy The firm said it's bullish on the semiconductor company. Morgan Stanley reiterates Walmart as overweight Morgan Stanley raised its price target on the stock to $89 per share from $82 ahead of earnings next week. Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with the stock heading into a Trump administration. Morgan Stanley upgrades International Flavors to overweight from equal weight Morgan Stanley said in its upgrade of International Flavors that the fragrance and spice company is undervalued. Morgan Stanley upgrades Viking to overweight from equal weight Morgan Stanley said it sees an attractive entry point for the cruise company.

Persons: it's bullish, NXPI, Mizuho, it's, Morgan Stanley, WMT, Tesla, VIK, Redburn, Ross, Robinson, Wells, Bristol Myers, MoffettNathanson, D.A, Davidson, Snowflake Organizations: Semiconductor, NXP Semiconductor, Nvidia, Mizuho, TAM, 4Q, Citi, Deutsche Bank, Deutsche, " Bank of America, & Co, Bank of America, Apple Locations: eCommerce, VIK, OW, Wells Fargo, Bristol

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ CVS is under pressure and considering a breakup. Here's why that could be risky
▼ + stars: | 2024-10-04 | by ( Annika Kim Constantino | Annika Kim Constantino Covers The Biotech | Pharmaceutical Industry For Cnbc Digital. | ) www.nbcnews.com time to read: +13 min

It’s time for a wellness check at CVS Health. But Caremark, in some cases, also funnels drug prescriptions to CVS retail pharmacies, he said. He said a spinoff of CVS’ retail pharmacies would be more likely. A general view shows a sign of CVS Health Customer Support Center in CVS headquarters of CVS Health Corp in Woonsocket, Rhode Island, U.S. October 30, 2023. Those actions will help the company achieve its target of 100- to 200-basis-points margin improvement in its Medicare Advantage business, CVS executives said in August.

Persons: Caremark, ”, eMarketer, Rajiv Leventhal, Karen Lynch, Lynch, Brian Kane, “, ” Jefferies, Brian Tanquilut, Elizabeth Anderson, Anderson, it’s, eMarketer’s Leventhal, ” Tanquilut, Ann Hynes, Tanquilut, “ they’re, they’re, Michael Cherny, Cherny, Faith Ninivaggi, Reuters Cherny, CVS, Tom Cowhey Organizations: CVS Health, CVS, CNBC, Aetna, Monday, Glenview Capital, Glenview, Evercore ISI, UnitedHealth, Humana, Walgreens, Street Health, Oak, Health, Mizuho, Amazon, Walmart, Oak Street, Leerink Partners, Affordable, Medicare, CVS Health Corp, Reuters, Centers, Medicaid Services Locations: U.S, Caremark, Aetna, Texas and Illinois, Woonsocket , Rhode Island

☆ CVS is under pressure and considering a break up. Here's why that could be risky
▼ + stars: | 2024-10-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +11 min

In this article CVS Follow your favorite stocks CREATE FREE ACCOUNTA sign outside of a CVS pharmacy store on February 07, 2024 in Miami, Florida. That means Caremark also sits at the intersection of CVS' retail pharmacy operation and its Aetna insurer, boosting the competitive advantage of both of the businesses. A workers stocks the shelves in a CVS pharmacy store on February 07, 2024 in Miami, Florida. An Oak Street Health clinic stands in a Brooklyn neighborhood on February 08, 2023 in New York City. A general view shows a sign of CVS Health Customer Support Center in CVS headquarters of CVS Health Corp in Woonsocket, Rhode Island, U.S. October 30, 2023.

Persons: Joe Raedle, Caremark, Rajiv Leventhal, Karen Lynch, Lynch, Brian Kane, Jefferies, Brian Tanquilut, Elizabeth Anderson, Anderson, it's, eMarketer's Leventhal, Tanquilut, Ann Hynes, Spencer Platt, they're, Michael Cherny, Cherny, Faith Ninivaggi Organizations: Getty, CVS Health, CVS, CNBC, Aetna, Monday, Glenview Capital, Glenview, UnitedHealth, Humana, Walgreens, Street Health, Oak, Health, Mizuho, Oak Street Health, Amazon, Walmart, Oak Street, Leerink Partners, Affordable, Medicare, CVS Health Corp Locations: Miami , Florida, U.S, Aetna, Caremark, Brooklyn, New York City, Texas and Illinois, Woonsocket , Rhode Island

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Walmart, Salesforce, Starbucks, Amazon & more
▼ + stars: | 2024-09-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Tuesday's biggest calls on Wall Street: Piper Sandler initiates Colgate-Palmolive and Church & Dwight as overweight Piper said both consumer products company offer an attractive risk/reward. Piper Sandler upgrades Salesforce to overweight from neutral Piper said it sees an attractive risk/reward for the stock. Bernstein reiterates Amazon as outperform Bernstein said advertising is "key to the bull case once again" for Amazon. Wedbush upgrades Comerica to outperform from neutral The firm added the regional bank to its best ideas list. " CFRA reiterates Nvidia as buy The firm says it sees Nvidia with "sustained compute demand" over the coming years.

Persons: Piper Sandler, Dwight, Piper, Baird, Jefferies, it's bullish, Raymond James reinstates Uber, Raymond James, Goldman Sachs, Goldman, KeyBanc, Morgan Stanley, immuno, Oppenheimer, Lowe's, Redburn, it's, Truist, Baird downgrades McKesson, Needham, Apple, Pinterest, Leerink, Guggenheim, Tesla, TSLA, Bernstein, CFRA Organizations: Colgate, Palmolive, Church, Jefferies, Starbucks, Avidity Biosciences, BP, Exxon, Costco, Walmart, Apple, GE Vernova, UBS, Citi, Mastercard, Visa, U.S, DOJ, Comerica, CMA, Nvidia

☆ 10 things to watch in the stock market Tuesday, including long-awaited China stimulus
▼ + stars: | 2024-09-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

China related stocks were on the move Tuesday after the People's Bank of China said it will cut interest rates. What the Jefferies downgrade misses is the market is giving Starbucks a pass as Niccol builds his team and makes changes. Truist downgraded Club holding Costco to a hold rating ahead of earnings, which are out after Thursday's close. The analysts still have a hold-equivalent rating on Club holding Home Depot but boosted their price target to $400 per share. China related stocks were on the move Tuesday after the People's Bank of China said it will cut interest rates.

Persons: Brian Niccol, Chipotle, Jefferies, Truist, Salesforce, Piper Sandler, Oppenheimer, Regeneron, Eli Lilly, Pinterest, —, Jeff Marks, Jim Cramer's, Jim Cramer, Jim Organizations: People's Bank of, Starbucks, Jefferies, Costco, Walmart, Analysts, Barclays, Constellation Brands, Oppenheimer, Justice Department, Visa, Bloomberg, Jim Cramer's Charitable, CNBC Locations: China, People's Bank of China, Japan

☆ Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. The company aims to trim R&D spending to a range of $3.6 billion to $3.8 billion in 2027, down from an expected $4.8 billion at the end of this year, according to a release. Moderna also has five non-respiratory products across cancer, latent viruses and rare diseases that could be approved by 2027, according to the company's release. The company expects 2025 revenue to come in at $2.5 billion to $3.5 billion. From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch.

Persons: Moderna, Stephane Bancel, Leerink, Mani Foroohar, Foroohar, Michael Yee, Bancel Organizations: Moderna, CNBC, Jefferies Locations: New York, U.S

☆ Stocks making the biggest moves midday: Cleanspark, Vaxcyte, Unity Software and more
▼ + stars: | 2024-09-03 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Cleanspark released its mining update for August, which showed that it mined 478 bitcoins last month. Vaxcyte – Shares were recently up more than 36% and earlier hit a record high after the vaccine company reported positive results from the Phase 1/2 study for its 31-valent pneumococcal conjugate vaccine candidate. Semiconductor stocks – Shares of some of the biggest chipmakers fell during the first trading session of the month. Last week, shares fell 19% on news of its filing delay and Hindenburg's disclosed short position. United States Steel – Shares fell around 6% after Vice President Kamala Harris opposed the planned sale of U.S. Steel to Japan's Nippon Steel at a Labor Day rally for union members in Pittsburgh.

Persons: Cleanspark, Vaxcyte, Leerink, Morgan Stanley, Redfin, Charles Liang, Hindenburg's, Hindenburg, Kamala Harris, Harris, Lisa Kailai Han, Pia Singh, Jesse Pound, Fred Imbert, Michelle Fox Organizations: Leerink Partners, Boeing, Riley Securities, Semiconductor, KLA, Nvidia, Micron Technology, Taiwan Semiconductor Manufacturing, Broadcom, Hindenburg, Securities and Exchange, United States Steel, Steel, Japan's Nippon Steel, Labor, U.S Locations: Wells, U.S, Pittsburgh, American

☆ More public healthcare companies will be taken private. Here's what PE firms are betting on.
▼ + stars: | 2024-08-12 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Read previewRevenue cycle management company R1 RCM just announced its acquisition by two private equity firms for a whopping $8.9 billion — signaling a long-awaited resurgence of big healthcare deals. Private equity's return to the sceneThe debt market is finally correcting for the types of deals healthcare companies have been waiting for. Revenue cycle management has long been a hot area for private equity firms. AdvertisementSpringer said she thinks private equity firms are "very unlikely to buy a care delivery company in this environment." Sen. Markey introduced the Health Over Wealth Act in July that would limit private equity investment in healthcare providers.

Persons: —, Augmedix, Altaris, hasn't, dealmakers, David Marks, They're, Thad Davis, haven't, Davis, Tanay Tandon, Commure, Athelas, it's, Rebecca Springer, we'll, Shiv Rao, Abridge Springer, she'd, Springer, Steward, Sen, Markey, Brian Snyder, Knight's Marks, I've, Marks Organizations: Service, Business, Holland &, Leerink Partners, Epic, Mayo Clinic, Reuters, Holland, FTC

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Here are Thursday's biggest analyst calls: Meta, Tesla, Reddit, Amazon, Wingstop, Arm, Dollar General, Carvana, Qualcomm, SoFi & more
▼ + stars: | 2024-08-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America reiterates Arm as buy Bank of America said it's sticking with the stock following earnings on Wednesday. Robinson to overweight from neutral JPMorgan upgraded the shipping company following its earnings. Barclays reiterates Meta as overweight Barclays says it's sticking with the Instagram parent following earnings on Wednesday. " Bernstein reiterates Qualcomm as outperform Bernstein says it's sticking with Qualcomm following earnings on Wednesday. Citi reiterates SoFi as buy Citi said it's getting more bullish on the stock following a series of investor meetings.

Persons: Goldman Sachs, Goldman, Morgan Stanley, Zeta, Oppenheimer, Etsy, Baird, Wolfe, Bill.com, Robinson, Raymond James, RDDT, Wells, David Lantz, Zack Fadem, Bernstein, Leerink, Cantor Fitzgerald, Tesla, Cantor, it's bullish, Morgan Stanley downgrades Voya, SoFi, it's Organizations: Mizuho, Bank of America, ARM, Zeta Global, Zeta, JPMorgan, GE, NFL, NBA, MLB, Nascar, Barclays, Meta, Qualcomm, SOX, Elon Musk's, Citi Locations: OW, 2H24, China, bullish

☆ Dexcom shares plunge more than 40%, head for worst day on record
▼ + stars: | 2024-07-26 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +4 min

Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop came in September 2017, when the shares plunged 33% in a day. Dexcom held its stock market debut in 2005. With Friday's selloff, Dexcom shares are down almost 50% for the year, while the S&P 500 is up 15%.

Persons: Dexcom, Kevin Sayer, we've, Sayer, JPMorgan's Robbie Marcus, Marcus, Jereme Sylvain, Sylvain, William Blair, Leerink, Stelo, Friday's Organizations: JPMorgan, U.S . Food, Drug Administration

☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
▼ + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.

Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive

☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.

Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black

Mike Kratky, 33, Leerink PartnersLeerink PartnersSector: Medical devices and technologyKratky's young career underwent a major shift in March 2020 — and it wasn't remote work. The Colgate University graduate thinks he's a better analyst for it because he now understands how readers of his research think. "The stock calls won't always go my way," Kratky said. All eight of the outperform-rated medtech stocks Leerink has covered since October have outperformed the S&P 500 and their industry index. The medtech industry is experiencing rapid change, particularly with the advent of GLP-1 drugs that treat obesity and diabetes.

Persons: Mike Kratky, Kratky, Leerink, He's, he's, Kratky's, — James Faris Organizations: Leerink Partners Leerink Partners, Nasdaq, Riley Securities, Colgate University, Tandem Diabetes Care Locations: Leerink

☆ Pfizer's drug for advanced lung cancer shows promising long-term trial results
▼ + stars: | 2024-05-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition. The drug, called Lorbrena, also cut the risk of the cancer progressing in patients' brains. Only about 5% of all non-small cell lung cancer patients have the mutation, which causes cancer cells to grow and spread abnormally. But Pfizer's drug isn't currently considered the standard – or the most appropriate and widely used – treatment for the condition. Nearly 300 people in the trial either received Lorbrena or Pfizer's older lung cancer drug Xalkori.

Persons: isn't, Chris Boshoff, Lorbrena, David Spigel, Sarah Cannon, Spigel, Andrew Berens, Pfizer's Boshoff Organizations: CHICAGO, Pfizer, CNBC, Lorbrena's, American Society of Clinical Oncology, Clinical Oncology, Sarah, Sarah Cannon Research Institute, Lorbrena, Leerink Locations: U.S, Chicago

☆ A corner of the cancer therapy market is heating up—Here are the names investors need to know
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +8 min

A $25 billion market Meanwhile, RBC Capital Markets sees a $25 billion market opportunity for the space. A name Jones likes is Perspective Therapeutics , which he rates outperform. CATX 1Y mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. So it's really an ideal profile," said Piper Sandler analyst Edward Tenthoff, who doesn't cover Perspective Therapeutics. Then there is Lantheus Holdings , which calls itself a radiopharmaceutical-focused company and has a $5.6 billion market cap.

Persons: There's, Eli Lilly, Myers, Jefferies, Andrew Tsai, radiopharma, Oppenheimer, Jeff Jones, FactSet, William Blair, Read, — it's, Andy Hsieh, Gregory Renza, Jones, Cantor Fitzgerald, Louise Chen, it's, Piper Sandler, Edward Tenthoff, Dan Lyons, Janus Henderson, Lantheus, Roanna Ruiz Organizations: Novartis, pharma, Mariana Oncology, Myers Squibb, AstraZeneca, Fusion Pharmaceuticals, RBC Capital Markets, TRT, Therapeutics, Alpha, Janus, Janus Henderson Investors, Lantheus Holdings, Lantheus, Leerink, ~$ Locations: Biopharma, Bristol, Mariana, radiopharma, New Jersey

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ Stocks with high dividend growth and free cash flow perform best whatever the weather, Wolfe says
▼ + stars: | 2024-03-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that offer high dividend growth and high free cash flow perform best no matter the economic weather, according to Wolfe Research. Here are a few stocks that fit the bill, according to Senyek: Online marketplace eBay was one of several stocks that Wolfe singled out. With its 4% yield, CVS is also a good buy for investors focusing on a high-dividend growth, high free cash flow strategy, Wolfe said. Following CVS' earnings release, investment bank Leerink initiated research coverage of the stock with an outperform rating , citing its cash potential. Other stocks Wolfe included on its list were Constellation Energy , Humana and Archer-Daniels-Midland .

Persons: Chris Senyek, Wolfe, UnitedHealth, Andrew Mok, Tom Cowhey, — CNBC's Michael Bloom Organizations: Wolfe Research, eBay, Barclays, Medicare, CVS, Constellation Energy, Humana, Archer, Daniels, Midland

☆ Amazon, CVS, and Walgreens went all in on primary care. Their bets are bleeding money.
▼ + stars: | 2024-03-06 | by ( ) www.businessinsider.com time to read: +8 min

In the past several years, Amazon, CVS Health, and Walgreens each spent billions to own primary-care companies. CVS bought Oak Street Health. Here's how the bets that Amazon, CVS, and Walgreens made are playing out. CVS is building more Oak Street clinics despite lossesAn Oak Street Health location in Elgin, Illinois during its grand opening. CVS is hoping to help Oak Street clinics get profitable quicker by driving more patients their way.

Persons: Andy Jassy, Thos Robinson, It's, JP Morgan, Berkshire Hathaway, Business Insider's Eugene Kim, Kim, they've, it's, VillageMD hasn't, Jefferies, Brian Tanquilut, Tanquilut, Lydia Ramsey, Mike Pykosz, Pykosz, Aetna, Michael Cherny Organizations: CVS Health, Walgreens, Amazon, CVS, Oak Street Health, Business, Aetna, Medical, Washington Post, Summit Health, Oak, Health Locations: Oak, VillageMD, Haven, Florida, Elgin , Illinois

☆ 'Exciting idea': Fund manager loves this pharma stock — and analysts see more upside ahead
▼ + stars: | 2024-02-29 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

But one firm in the wider ecosystem that's perhaps lesser known stands out to fund manager Freddie Lait, which is McKesson Corp — the U.S. pharmaceuticals distribution company. Calling the company an "exciting idea," Lait noted that the 100-year-old business is "very defensive and very diversified." Lait manages over $750 million collectively between two funds — the Latitude Horizon Fund and the Latitude Global Fund . Of the 19 analysts covering the stock, 14 give it a buy or overweight rating, while three have hold ratings and one has a sell rating. The average price target on the stock is $550.25, according to FactSet data, giving it potential upside of 6%.

Persons: Eli Lilly, Freddie Lait, Lait, —, That's, … It's, McKesson, MCK, — CNBC's Michael Bloom Organizations: Novo Nordisk, Latitude Investment Management, CNBC, U.S, Cardinal Health, McKesson Corp, JPMorgan, Rite Aid, receivables, Leerink Partners, pharma

☆ Jim Cramer: Viking Therapeutics' weight-loss data not enough to dethrone Eli Lilly in GLP-1s
▼ + stars: | 2024-02-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.

Persons: CNBC's Jim Cramer, Eli Lilly —, —, Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly

Search resuls for: "Leerink"

25 mentions found